<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1983">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135351</url>
  </required_header>
  <id_info>
    <org_study_id>821-21</org_study_id>
    <nct_id>NCT05135351</nct_id>
  </id_info>
  <brief_title>Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation</brief_title>
  <official_title>A Pilot, Randomized, Double-blind, Placebo-controlled Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphoma: The PRIMAL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Higher gut microbiome diversity has been associated with improved survival following&#xD;
      autologous stem cell transplantation in multiple myeloma and lymphoma, but no strategies have&#xD;
      been identified to date that specifically target the gut microbiome. We hypothesize that&#xD;
      prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at&#xD;
      time of stem cell engraftment.&#xD;
&#xD;
      To test this hypothesis, we propose a randomized, double-blind, placebo-controlled trial of&#xD;
      resistant starch versus placebo (maltodextrin) in patients with myeloma or lymphoma&#xD;
      undergoing autologous stem cell transplantation. Thirty subjects will be randomized 1:1 to&#xD;
      the RS or placebo arm, dosed at 20g daily for 3 days followed by an increased to 20g twice a&#xD;
      day mixed into a food item of the subject's choice. The intervention will begin approximately&#xD;
      10 days prior to stem cell infusion and will continue until the first day of neutrophil&#xD;
      engraftment (first day absolute neutrophil count &gt;500) or approximately 30 days in total.&#xD;
      Fecal samples will be collected at 4 timepoints for microbiome analysis: 1) at study&#xD;
      enrollment 2) day of stem cell infusion 3) day +7 post auto transplant and 4) first day of&#xD;
      engraftment defined as absolute neutrophil count &gt;500 (approximately 10-14 days&#xD;
      post-transplant).&#xD;
&#xD;
      The primary endpoint will be the difference in gut microbiome diversity between the RS and&#xD;
      placebo arm collected at the engraftment timepoint. Secondary endpoints will include dietary&#xD;
      evaluation to assess the impact of subject diet on microbiome response to intervention and&#xD;
      serum sample collection to assess differences to gut permeability during transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the intervention</measure>
    <time_frame>35 Days</time_frame>
    <description>To understand the feasibility of the intervention in the proposed study population by calculating the percentage of subjects who adhere to &gt;70% of scheduled doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Duration</measure>
    <time_frame>25 days</time_frame>
    <description>To evaluate the duration of hospitalization according to intervention assignment by measuring time from stem cell transplant to day of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Neutropenic Fever</measure>
    <time_frame>25 Days</time_frame>
    <description>To estimate the rate of neutropenic fever in the post-transplant setting according to intervention assignment. This is captured by cumulative incidence of neutropenic fever (ANC &lt;1000, temperature &gt;38.0⁰C) by day 30 according to intervention assignment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of broad-spectrum antibiotic exposure</measure>
    <time_frame>25 Days</time_frame>
    <description>To determine the rate of broad-spectrum antibiotic exposure during transplant according to intervention assignment by measuring the proportion of subjects receiving systemic antibiotic exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of gastrointestinal symptoms</measure>
    <time_frame>35 Days</time_frame>
    <description>To determine the rate of gastrointestinal symptoms according to intervention assignment by using the patient-reported gastrointestinal symptom rating scale (GSRS.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>resistant starch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resistant Starch</intervention_name>
    <description>A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to provide informed consent&#xD;
&#xD;
          2. Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
          3. Has pathologically confirmed multiple myeloma, Non-Hodgkin lymphoma (DLBCL, mantle&#xD;
             cell lymphoma, follicular lymphoma, or peripheral T-cell lymphoma), or Hodgkin&#xD;
             lymphoma as determined on medical record review per standard of care transplant&#xD;
             procedures (no tissue required for study)&#xD;
&#xD;
          4. Meeting a standard-of-care indication for autologous stem cell transplantation for the&#xD;
             above diseases as determined by the investigator&#xD;
&#xD;
          5. Adult Individuals (male or female) at least 19 years of age&#xD;
&#xD;
          6. Meeting indications and recommended for first autologous stem cell transplantation by&#xD;
             investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of bariatric surgery (i.e. gastric banding, sleeve gastrectomy, Roux-en-Y&#xD;
             bypass), chronic gastrointestinal disease including chronic diarrheal illness or&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          2. Previous intolerance to fiber supplementation&#xD;
&#xD;
          3. Allergy or intolerance to potato starch or maltodextrin&#xD;
&#xD;
          4. Subject unwilling to comply with stool sample collection&#xD;
&#xD;
          5. Not suitable for study participation due to other reasons at the discretion of the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D'Angelo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayson Henrickson, MS</last_name>
    <phone>402-559-3810</phone>
    <email>jayson.henrickson@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Taylor Johnson</last_name>
    <phone>402-559-0963</phone>
    <email>taylora.johnson@unmc.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Christopher Dangelo</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

